ArticleNPJ breast cancer2024

A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer.

Emi Noguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.